Method and composition for improving fertility health in female and male animals and humans

Information

  • Patent Grant
  • 7045151
  • Patent Number
    7,045,151
  • Date Filed
    Tuesday, September 24, 2002
    22 years ago
  • Date Issued
    Tuesday, May 16, 2006
    18 years ago
Abstract
In a new pharmaceutical combination, the herb, Vitex agnus-castus (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B12, iron, zinc and magnesium help promote womens' fertility. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motility. The amino acid, L-carnitine, promotes formation of healthy sperm.
Description
BACKGROUND OF THE INVENTION

Because of delayed child bearing, unhealthy diets and use of tobacco, caffeine, alcohol, drugs and environmental contaminants, difficulties in conceiving have been experienced.


Needs exist for pharmaceutical compounds that improve fertility in both women and men.


SUMMARY OF THE INVENTION

This invention provides combinations of bioeffecting compounds for promoting fertility in men and women. The combinations include nutritional components that benefit fertility health. All the components have been studied separately, to determine their individual efficacy. The invention provides the first products to put these components together synergistically in women's and men's formulations.


As many as 15% of couples in the U.S. have difficulty conceiving a child. In about one third of these cases, it is the man that is infertile; in another third, the female has fertility issues. The remaining is due to a combination of male and female fertility issues, or unknown causes. In many of these cases, causes of infertility are treatable. Nutritional and lifestyle changes should be the first step to increasing chances for conception. Smoking and caffeine, drug and alcohol consumption, environmental toxicants, and stress are related to infertility in men and women. Reproductive organs are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. A balanced, nutritional diet, and nutritional supplements with high antioxidant content can help reverse some of that damage. In women, hormone balance is critical to monthly ovulation and development of the corpus luteum (an ovarian follicle that release progesterone after release of the egg to prepare the uterus for implantation).


These and further and other objects and features of the invention are apparent in the disclosure, which include the above ongoing written specification with the claims.







DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention provides combinations of beneficial bioeffecting compounds for promoting fertility in women. The invention provides a scientifically validated herbal/nutritional blend for women to improve infertility by helping to regulate the menstrual cycle and correct hormone imbalance (corpus luteum insufficiency) without increased chances of multiple births associated with drug therapy. The combination of amino acids, herbs, vitamins and minerals improves overall health and helps with many of the deficiencies that decrease fertility.


The herb, Vitex agnus-castus (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B12, iron, zinc and magnesium help promote womens' fertility.


The invention provides combinations of beneficial bioeffecting compounds for promoting fertility in men. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motility. The amino acid, L-carnitine, promotes formation of healthy sperm.


The invention provides synergistic action of the combinations.


The two dietary supplements in male and female formulas are useful for men and women. Preferably, the distinct combinations are taken by both members of a couple in which the female age is between 21 and 46. The distinct combinations are useful for couples who have tried for 6 months or more, up to three years, to become pregnant without success. Preferably, patients take 2-4 capsules per day of the distinct formulas for three months. In women it is useful to record their basal temperature daily using thermometers and charts and to have their blood drawn for progesterone analysis at day 18-22 of the first menstrual cycle prior to taking the supplement. For men, it is useful to submit a sperm sample at the same time for analysis of count and motility. Prior to submitting sperm samples, 2-4 days abstinence is suggested for best results. No fevers over 101 degrees in the three months prior to taking the new combinations should be encountered. It is useful to repeat the analyses during the fourth menstrual cycle of the study. The first month is needed to develop baselines, followed by three months of taking the combinations product or placebo.


Preferred ranges of the combinations considered in percent by weight are:

















Components
Minimum %
Maximum %




















Women's formula





Vitex (chasteberry)
2
10



L-arginine
40
60



Green tea
5
20



Vitamin e
5
20



Selenium
.01
 1



Vitamins B6, B12
.01
 1



Folic acid
.01
 1



Iron
.1
 5



Magnesium
10
40



Zinc
1
 5



Men's Formula



L-carnitine
40
70



Ferulic acid in Dong Quai
.1
10



Vitamins C and E
10
40



Coenzyme coQ10
.1
 5



Selenium
.01
 1



Zinc
.1
10



B vitamins
.001
 1










Acceptable ranges of womens' and mens' formulations are:

















Components
Minimum %
Maximum %




















Women's Formula
1
20



Vitex (chasteberry)
20
70



L-arginine
0
30



Green tea
0
30



Vitamin E
0.1
30



Selenium
0
 2



Vitamins B6, B12
0
 2



Folic acid
0
 1



Iron
0
 7



Magnesium
5
50



Zinc
0
10



Men's Formula



L-carnitine
20
80



Ferulic acid in Dong Quai
0
20



Vitamins C and E
.01
40



Coenzyme coQ10
.01
10



Selenium
0
 3



Zinc
0
15



B vitamins
0
 5










Examples of useful formulations in percent by weight are:















Components



















Women's formula




Vitex (chasteberry)
 5



L-arginiue
 50



Green tea
 11



Vitamin B
 11



Selenium
  .6



Vitamins B6, B12
  .38



Folic acid
  .02



Iron
 1



Magnesium
 20



Zinc
 1




100%



Men's Formula



L-carnitine
 60



Ferulic acid in Dong Quad
 6



Vitamins C and B
 30



Coenzyme coQ10
 1



Selenium
 6



Zinc
 2



B vitamins
 4




100%










While the invention has been described with references to specific embodiments, modifications and variations of the invention may be constructed without departing from the scope of the invention, which is defined in the following claims.

Claims
  • 1. A pharmaceutical composition having fertility promoting activity in males comprising components present in the proportion in parts by weight of about 20 to 80% L-carnitine, about 5 to 30% vitamins C and E, about 0.1 to 10% coenzyme Q10, about 0.001 to 1% selenium, about 0.2 to 20% ferulic acid, about 0.1 to 2% zinc, and about 0.001 to 1% B vitamins.
  • 2. A pharmaceutical composition having fertility promoting activity in males comprising components present in the proportion in parts by weight of about 10 to 80% L-carnitine, about 5 to 50% vitamins C and E, about 0.1 to 15% coenzyme Q10, about 0.001 to 1% selenium, about 0.2 to 20% ferulic acid, about0.1 to 15% zinc, and about 0.001 to 1% B vitamins.
  • 3. The pharmaceutical composition of claim 2, further comprising components present in the proportion in parts by weight of about 60% L-carnitine, about 25% vitamins C and E, about 6% ferulic acid, about 5% zinc and B vitamins, about 5% coenzyme Q10, and about 0.6% selenium.
Parent Case Info

This application is a divisional of application Ser. No. 09/742,412 filed Dec. 22, 2000 now U.S. Pat. Nos. 6,497,885.

US Referenced Citations (60)
Number Name Date Kind
2878124 Kruckenberg Mar 1959 A
3015567 Hause et al. Jan 1962 A
3360374 Barr et al. Dec 1967 A
3970750 Brockemeyer et al. Jul 1976 A
4154813 Kleinberg May 1979 A
4168307 Okamoto et al. Sep 1979 A
4340592 Adibi Jul 1982 A
4388325 Orzalesi Jun 1983 A
4599232 Bertelli Jul 1986 A
4900566 Howard Feb 1990 A
4920098 Cotter et al. Apr 1990 A
4954526 Keefer Sep 1990 A
4957938 Anderson et al. Sep 1990 A
5032608 Dudrick Jul 1991 A
5034377 Adibi et al. Jul 1991 A
5036052 Ozeki et al. Jul 1991 A
5041429 Sawai et al. Aug 1991 A
5106836 Clemens et al. Apr 1992 A
5157022 Barbul Oct 1992 A
5171217 March et al. Dec 1992 A
5217997 Levere et al. Jun 1993 A
5221668 Henningfield et al. Jun 1993 A
5248688 Dudrick Sep 1993 A
5262435 Joshua et al. Nov 1993 A
5278189 Rath et al. Jan 1994 A
5288490 Budzynski et al. Feb 1994 A
5296246 Inoue et al. Mar 1994 A
5326569 Acosta et al. Jul 1994 A
5334617 Ulrich et al. Aug 1994 A
5364644 Walaszek et al. Nov 1994 A
5374651 Kilbourn et al. Dec 1994 A
5380945 Murad et al. Jan 1995 A
5385937 Stamler et al. Jan 1995 A
5385940 Moskowitz Jan 1995 A
5411956 Miyazaki et al. May 1995 A
5428070 Cooke et al. Jun 1995 A
5439938 Snyder et al. Aug 1995 A
5464644 Wullschleger et al. Nov 1995 A
5500266 Durnin Mar 1996 A
5523087 Shlyankevich Jun 1996 A
5543430 Kaesemeyer Aug 1996 A
5545414 Behr et al. Aug 1996 A
5576287 Zaloga et al. Nov 1996 A
5576351 Yoshimura et al. Nov 1996 A
5594032 Gonzalez-Cadavid et al. Jan 1997 A
5626883 Paul May 1997 A
5631031 Meade May 1997 A
5650418 Rath et al. Jul 1997 A
5730987 Omar Mar 1998 A
5767160 Kaesemeyer Jun 1998 A
5780039 Greenberg et al. Jul 1998 A
5852058 Cooke et al. Dec 1998 A
5861168 Cooke et al. Jan 1999 A
5883086 Craft Mar 1999 A
5891459 Cooke et al. Apr 1999 A
5897864 Cohen Apr 1999 A
5945452 Cooke et al. Aug 1999 A
6007824 Duckett et al. Dec 1999 A
6117872 Maxwell et al. Sep 2000 A
6156802 Mae et al. Dec 2000 A
Foreign Referenced Citations (14)
Number Date Country
441119 Aug 1991 EP
511587 Apr 1992 EP
511118 Oct 1992 EP
0546796 Jun 1993 EP
50 48189 Apr 1975 JP
57 5692 Jan 1982 JP
57 93913 Jun 1982 JP
58-55418 Apr 1983 JP
05-163139 Jun 1993 JP
06-321786 Nov 1994 JP
07 163269 Jun 1995 JP
WO93 18156 Sep 1993 WO
WO9401006 Jan 1994 WO
94 10015 Sep 1993 ZA
Related Publications (1)
Number Date Country
20030026851 A1 Feb 2003 US
Divisions (1)
Number Date Country
Parent 09742412 Dec 2000 US
Child 10252698 US